Reflections on the Institute of Medicine's systemic exertion intolerance disease.
Jason, Leonard A, Sunnquist, Madison, Brown, Abigail et al. · Polskie Archiwum Medycyny Wewnetrznej · 2015 · DOI
Quick Summary
The Institute of Medicine proposed renaming chronic fatigue syndrome to 'systemic exertion intolerance disease' (SEID) and created new diagnostic criteria. This editorial critiques that change, noting that most patients rejected the new name and the new criteria were not tested on actual patient populations before being recommended. The new criteria may incorrectly identify more people as having the disease while missing key features that define it.
Why It Matters
How ME/CFS is defined and named directly affects which patients receive diagnosis, what research is conducted, and how medical institutions allocate resources. This editorial highlights that major diagnostic changes should be validated scientifically and involve patient input—issues central to ensuring accurate diagnosis and appropriate research funding for the ME/CFS community.
Observed Findings
Patient surveys showed majority rejection of the new SEID name.
Predictions suggest the new criteria will dramatically increase reported prevalence rates.
The new criteria select for patients with fewer overall symptoms and less impairment than other existing diagnostic frameworks.
The IOM recommendations were not pre-evaluated with patient or professional stakeholder input.
Significant ambiguity exists in the new criteria regarding which exclusionary illnesses apply.
Inferred Conclusions
Major changes to disease nomenclature and diagnostic criteria require empirical validation against patient datasets before implementation.
Stakeholder engagement with patient communities is essential when revising case definitions that affect millions of people.
Diagnostic criteria lacking clarity about exclusionary conditions risk both over-diagnosis and misclassification.
The new SEID criteria may not adequately capture the severity and symptom profile of the most severely affected patients.
Remaining Questions
How would prevalence estimates differ if the new SEID criteria were prospectively validated against existing patient cohorts and control groups?
What This Study Does Not Prove
This is an editorial review rather than an empirical study with novel data collection. It does not present new experimental evidence or prospective data validation; instead, it critiques prior recommendations and references existing literature. It does not establish definitive prevalence rates under the new criteria, only suggests they would be higher.